Nicoletta Loggia
Director Técnico/Científico/I+D en ORCHARD THERAPEUTICS PLC .
Cargos activos de Nicoletta Loggia
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ORCHARD THERAPEUTICS PLC | Director Técnico/Científico/I+D | 09/09/2021 | - |
| CANDEL THERAPEUTICS, INC. | Director/Miembro de la Junta | 07/06/2023 | - |
| Independent Dir/Board Member | 07/06/2023 | - |
Historial de carrera de Nicoletta Loggia
Formación de Nicoletta Loggia.
| University of Pavia | Doctorate Degree |
Estadísticas
Internacional
| Reino Unido | 2 |
| Italia | 2 |
| Estados Unidos | 2 |
Operativa
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
| Director/Board Member | 1 |
Sectorial
| Health Technology | 3 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| CANDEL THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Nicoletta Loggia
- Experiencia
